{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T18:37:40Z","timestamp":1788633460876,"version":"build-2803163510"},"reference-count":52,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Vasc Med"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    The efficacy of venoactive drug (VAD) treatment for pelvic venous disorder (PeVD) has not been fully investigated. This study was aimed at evaluating the efficacy and safety of different diosmin-containing agents in women with PeVD.\n                    <jats:bold>Methods:<\/jats:bold>\n                    VENOTREAT was a single-center, randomized, open-label study included 150 women with symptomatic PeVD, who were allocated for the 2-month therapy a once-daily intake of: (1) micronized purified flavonoid fraction (MPFF) 1000 mg; (2) diosmin 600 mg, or (3) hesperidin and diosmin combination (HDC) 1000 mg. The effects on chronic pelvic pain (CPP), the time to pain relief, as well as adverse events (AEs) were investigated.\n                    <jats:bold>Results:<\/jats:bold>\n                    Patients receiving MPFF reported a CPP reduction, using visual analog scale (VAS) scores, from 5.7 \u00b1 0.8 to 2.8 \u00b1 0.4 (\n                    <jats:italic toggle=\"yes\">p<\/jats:italic>\n                    = 0.001) by day 7 and its elimination by day 28 in all cases. In the diosmin and HDC groups, the CPP reduction became significant by day 14 (VAS scores from 5.3 \u00b1 0.6 to 3.7 \u00b1 0.3 and from 5.1 \u00b1 0.3 to 3.5 \u00b1 0.2, respectively, both\n                    <jats:italic toggle=\"yes\">p<\/jats:italic>\n                    = 0.001), and pain was eliminated after 2 months in 37 and 35, and decreased in the remaining 13 and 15 patients to VAS scores 1.07 \u00b1 0.2 and 1.1 \u00b1 0.07, accordingly. AEs included headache, nausea, gastralgia, and diarrhea and were reported in 7.3% of cases in general and in 6%, 8%, and 8% of patients in the MPFF, diosmin, and HDC groups, respectively. No serious AEs were observed.\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    VAD treatment is effective and safe for eliminating CPP in PeVD. MPFF provides a faster and greater effect on venous CPP of venous origin.\n                    <jats:bold>ClinicalTrials.gov Identifier: NCT06584799.<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1177\/1358863x251362200","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T06:24:18Z","timestamp":1756189458000},"page":"590-598","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Venoactive drug treatment for patients with pelvic varicose veins: Results of the single-center, randomized, open-label study (VENOTREAT)"],"prefix":"10.1177","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2307-2176","authenticated-orcid":false,"given":"Sergey G","family":"Gavrilov","sequence":"first","affiliation":[{"name":"Savelyev University Surgical Clinic, Pirogov Russian National Research Medical University, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1984-1827","authenticated-orcid":false,"given":"Yekaterina P","family":"Moskalenko","sequence":"additional","affiliation":[{"name":"Savelyev University Surgical Clinic, Pirogov Russian National Research Medical University, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1344-6530","authenticated-orcid":false,"given":"Anastasiya S","family":"Grishenkova","sequence":"additional","affiliation":[{"name":"Savelyev University Surgical Clinic, Pirogov Russian National Research Medical University, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1977-2030","authenticated-orcid":false,"given":"Sergei V","family":"Chubchenko","sequence":"additional","affiliation":[{"name":"Savelyev University Surgical Clinic, Pirogov Russian National Research Medical University, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,8,25]]},"reference":[{"key":"e_1_3_2_2_2","article-title":"Phlebotonics for venous insufficiency","volume":"11","author":"Martinez-Zapata MJ","year":"2020","unstructured":"Martinez-Zapata MJ, Vernooij RW, Simancas-Racines D, et al Phlebotonics for venous insufficiency. Cochrane Database Syst Rev 2020; 11: CD003229.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejvs.2021.12.024"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvsv.2023.08.011"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19061669"},{"key":"e_1_3_2_6_2","first-page":"488","article-title":"Reduction of lower-limb edema in patients with chronic venous disease by micronized purified flavonoid fraction: A systematic literature review and meta-analysis","volume":"42","author":"Rabe E","year":"2023","unstructured":"Rabe E, Blanc-Guillemaud V, Onselaer MB, et al Reduction of lower-limb edema in patients with chronic venous disease by micronized purified flavonoid fraction: A systematic literature review and meta-analysis. Int Angiol 2023; 42: 488\u2013502.","journal-title":"Int Angiol"},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"143","DOI":"10.23736\/S0392-9590.18.03975-5","article-title":"Efficacy of micronized purified flavonoid fraction (Daflon\u00ae) on improving individual symptoms, signs and quality of life in patients with chronic venous disease: A systematic review and meta-analysis of randomized double-blind placebo-controlled trials","volume":"37","author":"Kakkos SK","year":"2018","unstructured":"Kakkos SK, Nicolaides AN. Efficacy of micronized purified flavonoid fraction (Daflon\u00ae) on improving individual symptoms, signs and quality of life in patients with chronic venous disease: A systematic review and meta-analysis of randomized double-blind placebo-controlled trials. Int Angiol 2018; 37: 143\u2013154.","journal-title":"Int Angiol"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.23736\/S0392-9590.18.03999-8"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.23736\/S0392-9590.20.04388-6"},{"key":"e_1_3_2_10_2","first-page":"465","article-title":"Systematic literature review and expert meeting report on health-related quality of life in chronic venous disease","volume":"42","author":"Ulloa JH","year":"2023","unstructured":"Ulloa JH, Lurie F, Santiago FR, et al Systematic literature review and expert meeting report on health-related quality of life in chronic venous disease. Int Angiol 2023; 42: 465\u2013476.","journal-title":"Int Angiol"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01219-y"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1177\/0268355517692221"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.23736\/S0392-9590.19.04237-8"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvsv.2020.12.084"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jogc.2021.08.011"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1102063"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvsv.2024.101865"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.23736\/S0392-9590.21.04579-X"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-021-00312-6"},{"key":"e_1_3_2_20_2","volume-title":"Medicines in Russia","author":"Vidal","year":"2023","unstructured":"Vidal. Vidal Handbook 2023 [in Russian]. Medicines in Russia. Vidal Rus, 2023."},{"key":"e_1_3_2_21_2","first-page":"139","article-title":"[Market research of phlebotropic drugs applied in treatment and prevention of chronic venous diseases]","volume":"24","author":"Chesnokova NN.","year":"2017","unstructured":"Chesnokova NN. [Market research of phlebotropic drugs applied in treatment and prevention of chronic venous diseases] [in Russian]. Kubanskij nauchnyj medicinskij vestnik 2017; 24: 139\u2013144.","journal-title":"Kubanskij nauchnyj medicinskij vestnik"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.3310\/hta20050"},{"key":"e_1_3_2_23_2","first-page":"96","article-title":"Effects of micronized purified flavonoid fraction (Daflon) on pelvic pain in women with laparoscopically diagnosed pelvic congestion syndrome: A randomized crossover trial","volume":"34","author":"Simsek M","year":"2007","unstructured":"Simsek M, Burak F, Taskin O. Effects of micronized purified flavonoid fraction (Daflon) on pelvic pain in women with laparoscopically diagnosed pelvic congestion syndrome: A randomized crossover trial. Clin Exp Obstet Gynecol 2007; 34: 96\u201398.","journal-title":"Clin Exp Obstet Gynecol"},{"key":"e_1_3_2_24_2","first-page":"46","article-title":"[Monitoring the quality of life in patients with varicose disease of the lower extremities in the use of Venarus]","volume":"6","author":"Sto\u012dko IuM","year":"2010","unstructured":"Sto\u012dko IuM, Gudymovich VG. [Monitoring the quality of life in patients with varicose disease of the lower extremities in the use of Venarus] [in Russian]. Khirurgiia (Mosk) 2010; 6: 46\u201351.","journal-title":"Khirurgiia (Mosk)"},{"key":"e_1_3_2_25_2","first-page":"93","article-title":"[Clinical efficacy of Detralex in treatment of women with pelvic varicose veins]","volume":"24","author":"Akhmetzianov RV","year":"2018","unstructured":"Akhmetzianov RV, Bredikhin RA. [Clinical efficacy of Detralex in treatment of women with pelvic varicose veins] [in Russian]. Angiol Sosud Khir 2018; 24: 93\u201399.","journal-title":"Angiol Sosud Khir"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.23736\/S0392-9590.19.04216-0"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2018.1552043"},{"key":"e_1_3_2_28_2","first-page":"4237204","article-title":"Is nonmicronized diosmin 600 mg as effective as micronized diosmin 900 mg plus hesperidin 100 mg on chronic venous disease symptoms? Results of a noninferiority study","volume":"2020","author":"Steinbruch M","year":"2020","unstructured":"Steinbruch M, Nunes C, Gama R, et al Is nonmicronized diosmin 600 mg as effective as micronized diosmin 900 mg plus hesperidin 100 mg on chronic venous disease symptoms? Results of a noninferiority study. Int J Vasc Med 2020; 2020: 4237204.","journal-title":"Int J Vasc Med"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.2147\/VHRM.S324112"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvsv.2021.04.019"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvsv.2023.08.009"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2007.02.062"},{"issue":"31","key":"e_1_3_2_33_2","first-page":"552","article-title":"Sample size calculation in clinical trials: Part 13 of a series on evaluation of scientific publications","volume":"107","author":"R\u00f6hrig B","year":"2010","unstructured":"R\u00f6hrig B, du Prel JB, Wachtlin D, et al Sample size calculation in clinical trials: Part 13 of a series on evaluation of scientific publications. Dtsch Arztebl Int 2010; 107(31-32): 552\u2013556.","journal-title":"Dtsch Arztebl Int"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1177\/0268355517723992"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvsv.2023.04.009"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/16.5.931"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-009-0951-1"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1994.160"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.17116\/flebo20159334-40"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11060521"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvsv.2020.09.003"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.1168"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1053\/ejvs.1998.0751"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.2174\/1570161113666150827124714"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1177\/000331970205300301"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-0884-4"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40267-019-00637-5"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.17116\/flebo202014031230"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02643-6"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02657-0"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aba2940"},{"key":"e_1_3_2_52_2","article-title":"Hemodynamic and neurobiological factors for the development of chronic pelvic pain in patients with pelvic venous disorder","volume":"11","author":"Gavrilov SG","year":"2023","unstructured":"Gavrilov SG, Karalkin AV, Mishakina NY, Grishenkova AS. Hemodynamic and neurobiological factors for the development of chronic pelvic pain in patients with pelvic venous disorder. J Vasc Surg Venous Lymphat Disord 2023; 11: 610\u2013618.e3.","journal-title":"J Vasc Surg Venous Lymphat Disord"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.avsg.2024.05.027"}],"container-title":["Vascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1358863X251362200","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1358863X251362200","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1358863X251362200","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T03:36:13Z","timestamp":1777692973000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1358863X251362200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,25]]},"references-count":52,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1177\/1358863X251362200"],"URL":"https:\/\/doi.org\/10.1177\/1358863x251362200","relation":{},"ISSN":["1358-863X","1477-0377"],"issn-type":[{"value":"1358-863X","type":"print"},{"value":"1477-0377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,25]]}}}